NEP Special Edition July 2021

Congress Symposia

Hypertension treatment in special populations | Symposium 8.3

New treatment targets to halt CKD progression | Symposium 4.1

New nutritional targets in CKD | Symposium 4.6

COVID-19 in haemodialysis patients | Symposium 5.2

ANCA vasculitis prognostic and treatment | Symposium 3.6

Complicated lupus nephritis | Symposium 3.5

Late Breaking Clinical Trials | Symposium 0.1

Microbiome in CKD | Symposium 4.2

New aspects in AKI prevention and treatment | Symposium 9.4

Recent advances in kidney transplantation: focus on immunity | Symposium 7.2

Diabetic nephropathy in 2021 | Symposium 8.2

Onconephrology | Symposium 3.4

Preeclampsia and kidney in 2021 | Symposium 2.3

Future scenarios for renal disease | Symposium 0.6

Industry Symposia

Targeting CKD Patients’ Quality of Life – Organised by FRESENIUS KABI

Addressing gaps in patient care in rare inherited disorders: the role of the nephrologist – Organised by CHIESI FARMACEUTICI S.P.A.

Advances in autosomal dominant polycystic kidney disease: improving patient care to slow disease progression – Organised by SANOFI GENZYME

GLP-1 receptor agonists and the kidney – Organised by NOVO NORDISK A/S

When delays could lead to ESKD. Identifying and managing primary hyperoxaluria in clinical practice – Organised by ALNYLAM PHARMACEUTICALS